SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial unveiling of ...
Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently endorse routine ...
ST. LOUIS, June 16, 2020 /PRNewswire/ -- Canopy Biosciences, a multi-omic CRO providing NanoString® nCounter® and RNA Seq services to both clinical and research customers, has partnered with OnRamp ...
Good afternoon and thank you for attending today’s NanoString First Quarter Operating Results Call. My name is Jason and I’ll be the moderator for today’s call. All lines will be muted during the ...
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic ...
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of the nCounter® PanCancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results